Pancreatic Cancer Research

ResearcherUniversity of VeronaActive in the last 2 years

William Greenhalf

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-1865-3195; OpenAlex author ID A5030627781, A5033662647, A5115593098, A5158545475. Sources: OpenAlex.

Their work

Papers
85 (first author 4, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
301
Papers, trials and grants by year

2011: 2 papers · 2012: 2 papers · 2013: 3 papers · 2014: 3 papers · 2015: 6 papers · 2016: 7 papers · 2017: 7 papers · 2018: 11 papers · 2019: 4 papers · 2020: 5 papers · 2021: 8 papers · 2022: 4 papers · 2023: 6 papers · 2024: 1 paper · 2025: 10 papers · 2026: 6 papers

Papers 50 of 85

  1. Risk-stratified surveillance for individuals in the UK at high risk of developing pancreatic cancer: Outcomes from the European Registry of Hereditary Pancreat… Co-author DOI 10.1016/j.ejca.2026.116592↗
  2. The benefit of deep genomic testing for asymptomatic high-risk individuals undergoing surveillance for pancreatic adenocarcinoma: European registry for heredit… Co-author DOI 10.1016/j.neo.2026.101316↗
  3. Publisher Correction: Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis. Co-author DOI 10.1038/s41467-026-69055-2↗
  4. NQO1 as a predictor of response to adjuvant GemCap treatment for pancreatic cancer. Co-author DOI 10.1093/jnci/djaf345↗
  5. A Comprehensive Assessment of the Causal Relationship between Atopic Conditions and Pancreatic Cancer Risk: A Two-Sample Mendelian Randomization Study. Co-author DOI 10.1158/1055-9965.epi-25-1601↗
  6. Predicting pancreatic cancer in high-risk individuals and in the general population: how long is the road yet? Co-author DOI 10.17235/reed.2026.12183/2026↗
  7. Cost-Effectiveness of Biomarker-Associated Early Pancreatic Cancer Detection in New-Onset Diabetes. Co-author DOI 10.1001/jamanetworkopen.2025.38031↗
  8. Polymorphisms within autophagy-related genes as susceptibility biomarkers for pancreatic cancer: A meta-analysis of three large European cohorts and functional… Co-author DOI 10.1002/ijc.35196↗
  9. Low type-2 immune effectors modulate atopic diseases' protective role in pancreatic cancer risk. Co-author DOI 10.1002/ijc.35397↗
  10. GATA6 immunohistochemistry and prognosis after surgical resection of pancreatic adenocarcinoma: results from the ESPAC-4 trial. Co-author DOI 10.1016/j.esmogo.2025.100138↗
  11. Biomarkers, omics and artificial intelligence for early detection of pancreatic cancer. Co-author DOI 10.1016/j.semcancer.2025.02.009↗
  12. Targeting pancreatic cancer screening by identification of pathogenic variants of BRCA2/ BRCA1 in healthy individuals who have no known family history of pancr… Last author DOI 10.1016/j.semcancer.2025.05.001↗
  13. Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis. Co-author DOI 10.1038/s41467-025-65811-y↗
  14. A pleiotropy scan to discover new susceptibility loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/mutage/geae012↗
  15. Prevalence of New-Onset Diabetes in Patients Undergoing Pancreatic Surgery and the Association of Glucose Dysregulation With Complications in Pancreatic Cancer. Co-author DOI 10.1097/as9.0000000000000584↗
  16. European Registry of Hereditary Pancreatic Diseases (EUROPAC): protocol for primary and secondary screening in individuals with inherited pancreatic disease sy… Co-author DOI 10.1136/bmjopen-2025-100027↗
  17. HLA-A*02:01allele is associated with decreased risk and a longer survival in pancreatic cancer: Results from an exhaustive analysis of theHLAvariation in PDAC Co-author DOI 10.1101/2024.08.29.24312704↗
  18. The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2023.104020↗
  19. Genetic and non-genetic risk factors for early-onset pancreatic cancer. Co-author DOI 10.1016/j.dld.2023.02.023↗
  20. GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/gutjnl-2021-325803↗
  21. Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance. Co-author DOI 10.1158/1940-6207.capr-22-0529↗
  22. Mutant K-Ras in Pancreatic Cancer: An Insight on the Role of Wild-Type N-Ras and K-Ras-Dependent Cell Cycle Regulation. Last author DOI 10.3390/cimb45030164↗
  23. The Potent G-Quadruplex-Binding Compound QN-302 Downregulates S100P Gene Expression in Cells and in an In Vivo Model of Pancreatic Cancer. First author DOI 10.3390/molecules28062452↗
  24. Concordance of human equilibrative nucleoside transporter-1 expressions between murine (10D7G2) and rabbit (SP120) antibodies and association with clinical out… Co-author DOI 10.1002/cnr2.1507↗
  25. Blood levels of adiponectin and IL-1Ra distinguish type 3c from type 2 diabetes: Implications for earlier pancreatic cancer detection in new-onset diabetes. Co-author DOI 10.1016/j.ebiom.2021.103802↗
  26. Standardization of EUS imaging and reporting in high-risk individuals of pancreatic adenocarcinoma: consensus statement of the Pancreatic Cancer Early Detectio… Co-author DOI 10.1016/j.gie.2021.10.025↗
  27. United Kingdom Early Detection Initiative (UK-EDI): protocol for establishing a national multicentre cohort of individuals with new-onset diabetes for early de… Co-author DOI 10.1136/bmjopen-2022-068010↗
  28. Recommendations for a More Organized and Effective Approach to the Early Detection of Pancreatic Cancer From the PRECEDE (Pancreatic Cancer Early Detection) Co… Co-author DOI 10.1053/j.gastro.2021.08.036↗
  29. Gallbladder disease and pancreatic cancer risk: a multicentric case-control European study. Co-author DOI 10.1097/cej.0000000000000588↗
  30. Deciphering the complex interplay between pancreatic cancer, diabetes mellitus subtypes and obesity/BMI through causal inference and mediation analyses. Co-author DOI 10.1136/gutjnl-2019-319990↗
  31. Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction. Co-author DOI 10.1136/jmedgenet-2020-106961↗
  32. Genetic Polymorphisms Involved in Mitochondrial Metabolism and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-21-0353↗
  33. A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer. Co-author DOI 10.1186/s13073-020-00816-4↗
  34. Identification of Recessively Inherited Genetic Variants Potentially Linked to Pancreatic Cancer Risk. Co-author DOI 10.3389/fonc.2021.771312↗
  35. hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. Last author DOI 10.3390/cancers13225758↗
  36. International consensus guidelines on surveillance for pancreatic cancer in chronic pancreatitis. Recommendations from the working group for the international … Co-author DOI 10.1016/j.pan.2020.05.011↗
  37. Early detection of pancreatic cancer. Co-author DOI 10.1016/s2468-1253(19)30416-9↗
  38. Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer. Co-author DOI 10.1093/jncics/pkz060↗
  39. Pancreatic Cancer Risk in Relation to Lifetime Smoking Patterns, Tobacco Type, and Dose-Response Relationships. Co-author DOI 10.1158/1055-9965.epi-19-1027↗
  40. A combination of urinary biomarker panel and PancRISK score for earlier detection of pancreatic cancer: A case-control study. Co-author DOI 10.1371/journal.pmed.1003489↗
  41. Pancreatic cancer and autoimmune diseases: An association sustained by computational and epidemiological case-control approaches. Co-author DOI 10.1002/ijc.31866↗
  42. Genetic determinants of telomere length and risk of pancreatic cancer: A PANDoRA study. Co-author DOI 10.1002/ijc.31928↗
  43. Identification of Cystic Lesions by Secondary Screening of Familial Pancreatic Cancer (FPC) Kindreds Is Not Associated with the Stratified Risk of Cancer. Last author DOI 10.1038/s41395-018-0395-y↗
  44. Familial pancreatic adenocarcinoma: A retrospective analysis of germline genetic testing in a French multicentre cohort. Co-author DOI 10.1111/cge.13629↗
  45. Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation. Co-author DOI 10.1002/ijc.31047↗
  46. Transcriptional variations in the wider peritumoral tissue environment of pancreatic cancer. Co-author DOI 10.1002/ijc.31087↗
  47. Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. Last author DOI 10.1038/s41416-018-0004-2↗
  48. Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pa… Last author DOI 10.1038/s41416-018-0005-1↗
  49. Therapeutic developments in pancreatic cancer: current and future perspectives. Co-author DOI 10.1038/s41575-018-0005-x↗
  50. Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2018.08.009↗

Closest collaborators

The 25 strongest of 301 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Eithne Costello · 54 shared papers, 2011–2026 · strength 4.56
  2. Christopher Michael Halloran · 23 shared papers, 2014–2026 · strength 2.87
  3. John P. Neoptolemos · 40 shared papers, 2011–2026 · strength 2.53
  4. Paula Ghaneh · 20 shared papers, 2014–2026 · strength 1.89
  5. Lucy S. Oldfield · 10 shared papers, 2016–2026 · strength 1.45
  6. Daniel H. Palmer · 16 shared papers, 2014–2025 · strength 1.42
  7. Jorg H. Kleeff · 14 shared papers, 2015–2025 · strength 1.09
  8. Núria Malats · 13 shared papers, 2015–2025 · strength 1.08
  9. Francisco X. Real · 13 shared papers, 2015–2025 · strength 1.05
  10. Daniele Campa · 8 shared papers, 2011–2026 · strength 1.00
  11. Alfredo Carrato · 12 shared papers, 2015–2025 · strength 0.96
  12. Markus Wolfgang Büchler · 16 shared papers, 2011–2025 · strength 0.94
  13. Julie Earl · 5 shared papers, 2015–2026 · strength 0.90
  14. Thilo Hackert · 9 shared papers, 2016–2026 · strength 0.89
  15. Tatjana Crnogorac‐Jurcevic · 11 shared papers, 2015–2025 · strength 0.89
  16. Thomas Mathias Gress · 10 shared papers, 2017–2025 · strength 0.84
  17. Annabelle Boughey · 3 shared papers, 2025–2026 · strength 0.83
  18. Christoph W. Michalski · 9 shared papers, 2013–2026 · strength 0.78
  19. Aldo Scarpa · 13 shared papers, 2013–2024 · strength 0.78
  20. Luis Muñoz‐Bellvís · 9 shared papers, 2017–2025 · strength 0.76
  21. J. Enrique Domínguez‐Muñoz · 9 shared papers, 2017–2025 · strength 0.76
  22. Stephen P. Pereira · 8 shared papers, 2015–2026 · strength 0.75
  23. Salvatore Paiella · 4 shared papers, 2021–2026 · strength 0.73
  24. Rita Teresa Lawlor · 9 shared papers, 2017–2025 · strength 0.72
  25. Irena Stefanova · 3 shared papers, 2025 · strength 0.67

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.